Media & Press releases

Media

MEDVALEE MONTPELLIER

May 22, 2024

Boost Invest Medvallée le dispositif s’affine et trouve ses cibles

LA METHODE SCIENTIFIQUE

June 20, 2022

Système nerveux : de l’autre côté du périphérique

BIOMEDICINES

June 19, 2022

Traumatic and diabetic Schwann cell demyelination is triggered by a transient mitochondrial calcium release through voltage dependent anion channel 1

BIOTECH FINANCES

February 21, 2022

Nervosave défie la CMT1A

LA MARSEILLAISE

April 30, 2021

Maladies de Charcot-Marie-Tooth : un espoir de traitement

Nature Communications

April 21, 2021

AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A

INSERM

April 21, 2021

La thérapie génique, un espoir contre les maladies de Charcot‑Marie‑Tooth

AFNP

La myéline du nerf périphérique

Myology 2019

April 2, 2019

Nicolas Tricaud et les maladies de Charcot-Marie-Tooth

INSERM

August 17, 2017

ERC Laureates 2012

Press releases

October 21, 2021

Foundation of Nervosave Therapeutics!

September, 2022

Sarah Abbas, MD, joins Nervosave Therapeutics as Chief Medical Officer

February, 2023

Nervosave Therapeutics set up a lab at Sanofi BioPark in Montpellier, France

September, 2023

Sam Azoulay, MD, MBA, joins Nervosave Therapeutics as consulting CEO